Investments
4Portfolio Exits
1Partners & Customers
10Penn Medicine Web Traffic
Penn Medicine Rank
Latest Penn Medicine News
May 18, 2022
Naomi Diaz - Wednesday, May 18th, 2022 Technology, combined with an imaging agent, can light up microscopic cancer cells that are typically not visible during biopsy, according to a May 17 study published in Nature Communications . Researchers from the Philadelphia-based Abramson Cancer Center at the University of Pennsylvania combined a cancer-targeted near-infrared tracer with a needle-based confocal laser endomicroscopy system to guide an imaging agent during biopsies, which lit up cancer cells, allowing real-time diagnosis to be completed. With the new technology, malignant or non-malignant tissue biopsies were detected with 96 percent accuracy and made no false negatives on 20 human biopsy specimens. "The emerging ability to light up a single cell that may be invisible to the eye provides great opportunity to give patients the best chance at an early diagnosis before cancer spreads," said Gregory Kennedy, MD, a resident in general surgery at Penn Medicine. "This unique approach has the potential to improve the information we get from biopsies and it may increase our chances of identifying cancer early." The researchers hope this approach can be used to help with earlier diagnosis of other cancer types, as current medical technology does not provide real-time diagnostic information during biopsy.
Penn Medicine Investments
4 Investments
Penn Medicine has made 4 investments. Their latest investment was in Interius BioTherapeutics as part of their Series A on May 5, 2021.
Penn Medicine Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
5/18/2021 | Series A | Interius BioTherapeutics | $76M | Yes | Agent Capital, Bain Capital Ventures, BrightEdge, Cormorant Asset Management, Fairmount Funds Management, Knollwood Investment Advisory, Logos Capital, Longwood Fund, Mark Foundation for Cancer Research, Osage University Partners, Pfizer Venture Investments, Quan Capital, RA Capital Management, Tellus BioVentures, and University of Pennsylvania | 14 |
3/1/2021 | Series B - II | |||||
6/27/2018 | Series A | |||||
1/16/2018 | Series A |
Date | 5/18/2021 | 3/1/2021 | 6/27/2018 | 1/16/2018 |
---|---|---|---|---|
Round | Series A | Series B - II | Series A | Series A |
Company | Interius BioTherapeutics | |||
Amount | $76M | |||
New? | Yes | |||
Co-Investors | Agent Capital, Bain Capital Ventures, BrightEdge, Cormorant Asset Management, Fairmount Funds Management, Knollwood Investment Advisory, Logos Capital, Longwood Fund, Mark Foundation for Cancer Research, Osage University Partners, Pfizer Venture Investments, Quan Capital, RA Capital Management, Tellus BioVentures, and University of Pennsylvania | |||
Sources | 14 |
Penn Medicine Portfolio Exits
1 Portfolio Exit
Penn Medicine has 1 portfolio exit. Their latest portfolio exit was Tissue Analytics on May 14, 2020.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
5/14/2020 | Acquired | 1 |
Date | 5/14/2020 |
---|---|
Exit | Acquired |
Companies | |
Valuation | |
Acquirer | |
Sources | 1 |
Penn Medicine Acquisitions
2 Acquisitions
Penn Medicine acquired 2 companies. Their latest acquisition was Lancaster Neuroscience & Spine Associates on January 03, 2019.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
1/3/2019 | Acquired | 1 | ||||
1/9/2018 |
Date | 1/3/2019 | 1/9/2018 |
---|---|---|
Investment Stage | ||
Companies | ||
Valuation | ||
Total Funding | ||
Note | Acquired | |
Sources | 1 |
Penn Medicine Partners & Customers
10 Partners and customers
Penn Medicine has 10 strategic partners and customers. Penn Medicine recently partnered with Evergreen Nephrology on March 3, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
3/11/2022 | Partner | United States | Effective January 1 , 2022 , the joint venture -- a 50/50 partnership between UPHS and Evergreen -- contracts with the Centers for Medicare and Medicaid Services to provide care for Medicare patients with kidney disease , including those receiving dialysis . | 2 | |
1/1/2022 | Partner | United States | Effective January 1 , 2022 , the joint venture -- a 50/50 partnership between UPHS and Evergreen Nephrology -- contracts with the Centers for Medicare and Medicaid Services to provide care for Medicare patients with kidney disease , including those receiving dialysis . | 1 | |
11/29/2021 | Partner | United States | 1 | ||
9/23/2021 | Partner | ||||
5/11/2021 | Partner |
Date | 3/11/2022 | 1/1/2022 | 11/29/2021 | 9/23/2021 | 5/11/2021 |
---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Partner |
Business Partner | |||||
Country | United States | United States | United States | ||
News Snippet | Effective January 1 , 2022 , the joint venture -- a 50/50 partnership between UPHS and Evergreen -- contracts with the Centers for Medicare and Medicaid Services to provide care for Medicare patients with kidney disease , including those receiving dialysis . | Effective January 1 , 2022 , the joint venture -- a 50/50 partnership between UPHS and Evergreen Nephrology -- contracts with the Centers for Medicare and Medicaid Services to provide care for Medicare patients with kidney disease , including those receiving dialysis . | |||
Sources | 2 | 1 | 1 |
Penn Medicine Team
19 Team Members
Penn Medicine has 19 team members, including current Chief Executive Officer, Theresa Larivee.
Name | Work History | Title | Status |
---|---|---|---|
Theresa Larivee | Chief Executive Officer | Current | |
Meredith Fox | Temple University Health System, and McGladrey | Chief Financial Officer | Current |
Julia Puchtler | Chief Financial Officer | Current | |
Lu Ann Brady | Chief Operating Officer | Current | |
Thomas Gakis | Chief Operating Officer | Current |
Name | Theresa Larivee | Meredith Fox | Julia Puchtler | Lu Ann Brady | Thomas Gakis |
---|---|---|---|---|---|
Work History | Temple University Health System, and McGladrey | ||||
Title | Chief Executive Officer | Chief Financial Officer | Chief Financial Officer | Chief Operating Officer | Chief Operating Officer |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.